Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.
Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.
Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.
Having initially targeted $115m in proceeds, the genome sequencing spinout of Stanford has closed its offering at $140m after a full exercise of the overallotment option.
Stanford's Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.
Personalis has filed to list on the Nasdaq Global Market through an offering that would come eight years after the genome sequencing platform was spun out of Stanford University.
Karolinska Development-backed regenerative implant producer OssDsign has booked $15.8m after selling out the original issue for its forthcoming listing, and is now looking to generate up to $2.4m from the overallotment.
Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.